Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.

PINL:GRPOF - Post by User

Traxion Sab De Cv Ord Shs > Audio Review - Guy Chamberland - Key takeaways...

<< Previous

Bullboard Posts

Next >>

Comment by Tameraqon May 10, 2018 5:36am

232 Views

Post# 28009587

RE:Audio Review - Guy Chamberland - Key takeaways...

LeafRider wrote: I wanted to break this down a little because there are piles of good things mentioned in the podcast that should be documented IMO.

See the 5min mark which identifies the Health Canada regulations regarding "unique claims" regarding anything on the market after legalization occurs. Proves that all products on the shelf making health claims will require clinical trials as part of the validation and in order to be an OTC product period. There will be very little opportunity for products that don't have clinicals to make health claims.

Follow that by listening to the 8 min. mark regarding PPP005 clinical study on cannabis oil. Seeing how PPP005 - Cannabis oil clinical study is coverting "3 different cannabis oils, 1:1 1:2 and High-CBD", it will prove to be very lucrative down the line. It's good to know this study isn't just RxPrinceps Cannabis oil... followed by 9:17 - interesting comment about "concomitant medication"

"Concomitant drugs are two or more drugs used or given at or almost at the same time (one after the other, on the same day, etc.). The term has two contextual uses: as used in medicine or as used in drug abuse."

- I shouldn't have to point to the obvious respect to what Tetra is doing here. These clinical trials are a perfect stepping stone for us and for Aphria to get products to market that will have DIN#'s and even validation in order to be sold in some markets.

Around the 7min. mark Guy was asked... "How big is the market space for PPP001" - This was a slight miss on the response from Guy, who basically spoke to the timing, but not the "size of the market", I'm confident their forecasts are quite significant, but until investors can wrap their head around the monetary potential of these drugs internationallly (market size and forecasted market share), we're unlikely to be rewarded with a SP uptick. Moving forward hopefully we hear and read more about these real numbers and forecasts thoughout various jurisdictions.

Link to Audio: https://upticknewswire.com/featured-interview-guy-chamberland-chief-scientific-officer-of-tetra-bio-pharma-inc-2/